In clinical trials, Tibotec's latest drug, Intelence, has been found to be effective for many HIV-infected patients who are NNRTI-resistant and whose infections are not responding to currently available medications. It is widely expected to be prescribed and used in conjunction with other AIDS drugs as part of salvage regimens for patients whose previous drug combinations have failed them.
"As many states and the federal government also face significant budget
constraints and are drastically cutting budgets and services, we question
Tibotec's judgment and timing in pricing this latest AIDS drug so high,"
added AHF's Weinstein. "When Governor Schwarzenegger proposed eliminating
$7 million in drugs for co-morbidities and opportunistic infections from
the ADAP formulary last week, AIDS Healthcare Foundation said that instead
of cutting any drugs from the ADAP formulary, the Governor and state
lawmakers should instead reduce reimbursements to drug companies and try to
purchase drugs for ADAP and other crucial state programs at federal pricing
levels such as those that the Department of Veterans Affairs has
successfully negotiated with the industry. We vow to work in Sacramento and
in Washington to ensure that ADAP and
|SOURCE AIDS Healthcare Foundation|
Copyright©2008 PR Newswire.
All rights reserved